An Ultra-Sensitive Immunoassay for Quantifying Biomarkers in Breast Tumor Tissue
Open Access
- 1 January 2014
- journal article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 5 (2) , 115-124
Abstract
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) have been validated at the highest level of evidence as clinical biomarkers of prognosis in breast cancer. The American Society of Clinical Oncology recommends using uPA and PAI-1 levels in breast tumors for deciding whether patients with newly diagnosed node-negative breast cancer can forgo adjuvant chemotherapy. The sole validated method for quantifying uPA and PAI-1 levels in breast tumor tissue is a colorimetric ELISA assay that takes 3 days to complete and requires 100-300 mg of fresh or frozen tissue. In this study we describe a new assay method for quantifying PAI-1 levels in human breast tumor tissue. This assay combines pressure-cycling technology to extract PAI-1 from breast tumor tissue with a highly sensitive liposome polymerase chain reaction immunoassay for quantification of PAI-1 in the tissue extract. The new PAI-1 assay method reduced the total assay time to one day and improved assay sensitivity and dynamic range by >100, compared to ELISA.Keywords
This publication has 51 references indexed in Scilit:
- Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × DocetaxelBMC Cancer, 2011
- UPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers.Current Medicinal Chemistry, 2010
- A New Look at Node-Negative Breast CancerThe Oncologist, 2010
- Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcomeJournal of Cancer Research and Clinical Oncology, 2010
- The Urokinase Plasminogen Activator System: A Target for Anti-Cancer TherapyCurrent Cancer Drug Targets, 2009
- Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.International Journal of Molecular Medicine, 2008
- Procedures for the Quantitative Protein Determination of Urokinase and Its Inhibitor, PAI-1, in Human Breast Cancer Tissue Extracts by ELISA2005
- Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cellsBlood, 2004
- The urokinase plasminogen activator system as a target for prognostic studies in breast cancerBreast Cancer Research and Treatment, 1998
- Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast CancerSeminars in Thrombosis and Hemostasis, 1991